TIL Desk/Business/New Delhi/ Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19.
The company was reacting to a letter sent by India’s drug regulator DCGI seeking clarifications on the concerns raised and allegations made by a Member of Parliament.
DCGI on Sunday had sought clarification from Glenmark over its alleged “false claims” about the use of FabiFlu on COVID-19 patients with comorbidities and also over the “pricing” of the drug, after receiving a complaint from a Member of Parliament.
“Compared to other therapies approved for emergency use in COVID-19, FabiFlu is much more economical and an effective treatment option…,” Glenmark said in a filing to BSE.
